Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how CAR-T hopeful CNCT-19 or anti-CD38 antibody CID-103 might reshape future revenue is difficult when CASI Pharmaceuticals disclosures stretch across dozens of forms. Even the most diligent reader of the CASI Pharmaceuticals annual report 10-K simplified can miss key details on EVOMELA® sales in China, while keeping tabs on CASI Pharmaceuticals insider trading Form 4 transactions adds another layer of complexity.
Stock Titan eliminates that friction. Our AI reviews every CASI Pharmaceuticals quarterly earnings report 10-Q filing, each CASI Pharmaceuticals 8-K material events explained, and the full CASI Pharmaceuticals proxy statement executive compensation the moment EDGAR publishes them. The result: "understanding CASI Pharmaceuticals SEC documents with AI" shifts from aspiration to reality. Need alerts on CASI Pharmaceuticals Form 4 insider transactions real-time? We surface them in seconds, highlighting buys or sells that often precede critical trial readouts.
Put the insights to work:
- Run CASI Pharmaceuticals earnings report filing analysis to see R&D spend, cash runway, and segment revenue without combing through tables.
- Track CASI Pharmaceuticals executive stock transactions Form 4 against upcoming regulatory milestones.
- Get "CASI Pharmaceuticals SEC filings explained simply" summaries for risk factors, pipeline updates, and licensing agreements.
From real-time updates to plain-English explanations, Stock Titan delivers a complete view of CASI’s regulatory narrative—saving hours and empowering faster, better-informed decisions.
Panacea Venture Healthcare Fund II, L.P., its GP and parent entities, and Managing Partner James Huang filed Amendment No. 6 to Schedule 13G for CASI Pharmaceuticals (ticker: CASI) as of 30 Jun 2025.
The group reports beneficial ownership of 2,161,571 ordinary shares, equal to 13.8 % of the 15,506,348 shares outstanding. Of this, the fund holds 2,050,000 shares (13.2 %), while Huang controls options for 111,571 shares that are currently exercisable. Voting and dispositive power over the fund’s shares are shared among the Cayman-registered entities; Huang has sole power over his option shares.
The filers certify the stake was not acquired to influence control. No purchase prices or transaction dates beyond the record date are provided; the amendment chiefly refreshes ownership percentages and organizational details.
AAR Corp. (FY ended 31 May 2025) reported strong top-line momentum. Consolidated sales rose $461.6 M, or 19.9%, driven mainly by commercial demand and the late-FY24 Product Support acquisition. Commercial revenue grew $338.2 M (+20.6%); government revenue increased $123.4 M (+18.1%). Segment mix: Parts Supply 40% of sales, Repair & Engineering 32%, Integrated Solutions 25%, Expeditionary Services 3%.
Key portfolio moves included the sale of the Landing Gear Overhaul business to GA Telesis for $48 M, producing a $71.1 M divestiture loss, and a $2.1 M gain on exit of an Indian MRO JV. Integration of FY24’s Product Support buy and FY23’s Trax software investment is yielding cost synergies and digital upselling opportunities.
Growth pipeline: new multi-year distribution deals (Unison, Chromalloy, Ontic), an extended FTAI Aviation USM agreement (CFM56 through 2030) and two U.S. Navy P-8A support contracts. Firm backlog stands at $537.2 M (�75% recognizable in FY26). Airframe MRO capacity is expanding via 114 k sq ft Miami and 80 k sq ft Oklahoma City hangars, targeted for service within 12-18 months (Miami slightly delayed by permitting).
Government exposure remains meaningful: U.S. government agencies and contractors accounted for $687.6 M, 24.7% of revenue. Shares outstanding on 30 Jun 2025 were 35.85 M; non-affiliate market value was ~$2.43 B (11 Nov 2024 close). Workforce totals 5,600 employees and 500 contractors.
On June 30, 2025, MediaAlpha, Inc. (NYSE: MAX) filed a Form 8-K announcing technology-leadership changes and related compensation matters.
Item 5.02 � Executive transition. Chief Technology Officer Eugene Nonko resigned effective June 30, 2025, and simultaneously entered into a Fifth Amendment to his employment agreement to remain as Chief Architect, a non-executive individual-contributor role.
- Base salary: unchanged at $550,000 for 2025.
- Cash incentive bonus: 100 % of salary for 1H25 and 70 % for 2H25, delivering a blended 85 % target, or $467,500, subject to the same corporate metrics used for other senior executives.
- Equity awards: (1) Previously granted RSUs with a $2.75 million grant-date value (50 % of his $5.5 million CTO target opportunity); (2) an additional RSU award valued at $750,000 will be granted 15 July 2025, calculated by dividing $750,000 by the 20-day average share price. All RSUs vest in 16 equal quarterly instalments beginning 15 Aug 2025, contingent upon continued service.
The amendment is filed as Exhibit 10.1.
Item 7.01 � Regulation FD. The company furnished a press release (Exhibit 99.1) announcing the appointment of Amy Yeh as the new Chief Technology Officer. The information under Item 7.01 is considered “furnished,� not “filed,� under the Exchange Act.
FAQ
What is the current stock price of Casi Pharmaceuticals (CASI)?
What is the market cap of Casi Pharmaceuticals (CASI)?
What is the primary focus of CASI Pharmaceuticals Inc?
Which therapeutic areas does CASI primarily target?
How does CASI Pharmaceuticals generate revenue?
What are some key products or candidates in CASI’s portfolio?
How does CASI differentiate itself in the competitive biopharmaceutical market?
What role does clinical research play in CASI’s strategy?
How does CASI navigate complex regulatory environments?
What is the significance of CASI’s global commercial strategy?
Can you explain CASI's approach to innovation?
How does transparency factor into CASI’s operations?
